AFR Exclusive, page-80

A video of the presentation referred to by Taurean 7 is available on -

https://www.youtube.com/watch?v=jJKjwdgR7Qk

I would recommend a look for any AN1 shareholder.

Attached below are two slides from the presentation. The first represents their time-line for 2022-2023 whilst the second, below it, quotes the market potential relevant to the type of drug being developed by ROQ and the various applications.

Roquefort are concentrating initially on anti-cancer applications and believe they will be in clinical trials with it in 2023. The presentation quotes (see the bottom of the attached slides) two relevant drug partnerships, referred to by Taurean 7, that were enacted at a similar pre-clinical or phase 1 trial stage with partnership deals of $2 Billion.

Very optimistic indeed but an 8% cut of a $2 Billion deal would certainly put a smile on the face of AN1 shareholders.

poorinvestor